Core Viewpoint - The Jiangsu Medical Device Technology Industrial Park, Medpark, is experiencing significant growth and innovation, positioning itself as a key player in the high-end medical device industry, with a focus on research, production, and sales [1][10]. Group 1: Innovation and Development - The park has seen the signing of major projects, such as the headquarters of Shangmei Medical Group, which aims to create a comprehensive base for research, production, and sales [1]. - Numerous products from the park have been included in Jiangsu Province's innovative medical device catalog, showcasing the park's commitment to innovation [1]. - Companies like Suzhou Langmu Medical Technology are developing groundbreaking products, such as a micro-invasive glaucoma stent, which addresses a significant clinical need in China [2]. Group 2: Achievements and Recognition - The park has achieved notable milestones, including the establishment of national standards for wearable brain-machine interface products and the approval of various medical devices by the FDA [3][4]. - Medpark has been recognized with multiple awards, including being named a top 30 most vibrant biopharmaceutical industrial park in China [4]. Group 3: Support and Services - Medpark offers a comprehensive public service system, including high-level research institutions and a unique high-end medical device technology innovation center, which supports companies in their development processes [5][6]. - The park has implemented a "2+5+N" service system, providing tailored support for companies at various stages of development, including financial and legal services [8][9]. Group 4: Market Potential and Future Outlook - The medical device industry is characterized as a "sunrise industry," with significant growth potential driven by innovation and technological advancements [1][10]. - The park aims to accelerate its growth towards becoming a billion-level medical device industry base, leveraging its resources and services to support enterprise development [1][10].

深创投新材料基金领投。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 诺一迈尔同步推进国际化布局，2024年，公司创新医疗器械Neosprout鼻腔止血海绵产品相继获得 CE MDR和FDA批准上市；此外，多款创新医疗器械正在同步进行海外注册和市场推广。 诺一迈尔已经设立苏州、潍坊、太仓、上海四个研发生产基地，北京医学中心和德国弗莱堡海外实验 室，形成了"4+1+1"的研发创新架构。公司已建成洁净厂房总面积超过3万平方米，可快速响应下游 需求，为临床医生和患者提供了可靠的解决方案和产品，贡献于当地经济发展，带动就业。 诺一迈尔表示，非常感谢新材料基金对诺一迈尔的支持，及全体老股东对公司的信任。诺一迈尔已迈 入加速商业化落地的关键阶段，公司将继续秉持"创新+国际化"的发展战略，提供更丰富的产品组合 造福全球患者。 本文由公众号IPO早知道（ID：ipozaozhidao）原创撰写，如需转载请联系C叔↓↓↓ 据IPO早知道消息，近日，诺一迈尔（苏州）医学科技有限公司（下称"诺一迈尔"）宣布完成近3亿 元C轮融资，由深创投制造业转型升级新材料基金领投，部分老股东及管理层跟投，凯乘资本担任 ...